Harvard Apparatus Regenerative Technology Inc

BSTG.PK

$

Closing

1D

YTD

HRGN

No FIGI found

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

-4060.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

-62.00

Company Profile

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma or birth defects. Its Cellframe/Cellspan technology utilizes a biocompatible scaffold that is seeded with the patient’s own cells to create a Cellspan implant. Its product candidate includes Cellspan Esophageal Implant, Cellspan Bronchial Implants and Cellspan Tracheal Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection. Cellspan Tracheal Implants allow for the reconstruction of any portion of the trachea, potentially restoring its functional integrity. It is also launching a consumer medicine division to promote advanced anti-aging technology and products in China.